# LianBio (stock symbol: LIAN) Logo in transparent PNG and SVG formats

## LianBio Logo large

### LianBio Logo large Download PNG (105.45 KB)

![LianBio Logo large Download PNG (105.45 KB)](/img/orig/LIAN_BIG-1d854c1e.png)

### LianBio Logo large Download SVG (15.38 KB)

![LianBio Logo large Download SVG (15.38 KB)](/img/orig/LIAN_BIG-32533067.svg)

## LianBio Logo icon format

### LianBio Logo icon format Download PNG (28.77 KB)

![LianBio Logo icon format Download PNG (28.77 KB)](/img/orig/LIAN-a2ad1c06.png)

### LianBio Logo icon format Download SVG (1.02 KB)

![LianBio Logo icon format Download SVG (1.02 KB)](/img/orig/LIAN-4e5dd2c0.svg)

## LianBio Logo large for dark backgrounds

### LianBio Logo large for dark backgrounds Download PNG (68.76 KB)

![LianBio Logo large for dark backgrounds Download PNG (68.76 KB)](/img/orig/LIAN_BIG.D-54c80300.png)

### LianBio Logo large for dark backgrounds Download SVG (16.24 KB)

![LianBio Logo large for dark backgrounds Download SVG (16.24 KB)](/img/orig/LIAN_BIG.D-724d8935.svg)

## About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

1. Website domain: lianbio.com
2. Employees: 107
3. Marketcap: $0.23 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
